Learn about timing, dosing strategies, administration routes, and physician-supervised approaches
FDA materials flag compounded injectable GHK-Cu as a safety concern because of limited human safety data, aggregation risk, peptide-related impurities, and possible immunogenicity [8]
Still billing J0610 after April 1, 2023: The most common and most preventable error
(See also point 3 and 4, note 2) Supplementation (1000 mcg hydro(xo)cobalamine B12 injections, 2 times a week intramuscularly or deep subcutaneously for five weeks, or once a week for ten weeks) is primarily done when deficiency has been diagnosed
Retatrutide is an investigational triple receptor agonist still in clinical trials, while GHK-Cu is a copper-binding tripeptide used legally only in topical cosmetics in the UK
Cyanocobalamin is more commonly used in supplements and prescriptions due to its stability and lower cost